Rocket Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Rocket Pharmaceuticals, Inc. (RCKT) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-02-26
- Rocket Pharmaceuticals, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 0.00%.
- Rocket Pharmaceuticals, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.00%.
- Rocket Pharmaceuticals, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -0.20%.
- Rocket Pharmaceuticals, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -1.00%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-02-26 | |
| 2024-12-31 | 0.00% 10-K · filed 2026-02-26 | -0.60% 10-K · filed 2025-02-27 |
| 2023-12-31 | -0.20% 10-K · filed 2025-02-27 | |
| 2022-12-31 | -1.00% 10-K · filed 2025-02-27 | |
| 2021-12-31 | -0.10% 10-K · filed 2024-02-27 | -0.20% 10-K · filed 2022-02-28 |
| 2020-12-31 | -0.50% 10-K · filed 2023-02-28 | |
| 2019-12-31 | 2.10% 10-K · filed 2022-02-28 | |
| 2018-12-31 | -1.60% 10-K · filed 2021-03-01 | |
| 2017-12-31 | 0.00% 10-K · filed 2019-03-08 | -6.04% 10-K · filed 2018-03-07 |
| 2016-12-31 | 0.00% 10-K · filed 2019-03-08 | -1.74% 10-K · filed 2017-03-16 |
| 2015-12-31 | -3.35% 10-K · filed 2017-03-16 | |
| 2014-12-31 | -4.28% 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |